Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 163
Filtrar
Más filtros

País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Nature ; 557(7704): 177-182, 2018 05.
Artículo en Inglés | MEDLINE | ID: mdl-29720658

RESUMEN

Loss of dopamine in Parkinson's disease is hypothesized to impede movement by inducing hypo- and hyperactivity in striatal spiny projection neurons (SPNs) of the direct (dSPNs) and indirect (iSPNs) pathways in the basal ganglia, respectively. The opposite imbalance might underlie hyperkinetic abnormalities, such as dyskinesia caused by treatment of Parkinson's disease with the dopamine precursor L-DOPA. Here we monitored thousands of SPNs in behaving mice, before and after dopamine depletion and during L-DOPA-induced dyskinesia. Normally, intermingled clusters of dSPNs and iSPNs coactivated before movement. Dopamine depletion unbalanced SPN activity rates and disrupted the movement-encoding iSPN clusters. Matching their clinical efficacy, L-DOPA or agonism of the D2 dopamine receptor reversed these abnormalities more effectively than agonism of the D1 dopamine receptor. The opposite pathophysiology arose in L-DOPA-induced dyskinesia, during which iSPNs showed hypoactivity and dSPNs showed unclustered hyperactivity. Therefore, both the spatiotemporal profiles and rates of SPN activity appear crucial to striatal function, and next-generation treatments for basal ganglia disorders should target both facets of striatal activity.


Asunto(s)
Dopamina/metabolismo , Discinesias/patología , Discinesias/fisiopatología , Neuronas/metabolismo , Trastornos Parkinsonianos/patología , Trastornos Parkinsonianos/fisiopatología , Animales , Señalización del Calcio , Dopamina/deficiencia , Discinesias/etiología , Discinesias/metabolismo , Femenino , Levodopa/metabolismo , Levodopa/farmacología , Masculino , Ratones , Modelos Biológicos , Movimiento/efectos de los fármacos , Neostriado/metabolismo , Neostriado/patología , Neostriado/fisiopatología , Trastornos Parkinsonianos/metabolismo , Receptores de Dopamina D1/agonistas , Receptores de Dopamina D1/metabolismo , Receptores de Dopamina D2/agonistas , Receptores de Dopamina D2/metabolismo
2.
Am J Hum Genet ; 104(5): 948-956, 2019 05 02.
Artículo en Inglés | MEDLINE | ID: mdl-30982612

RESUMEN

The occurrence of non-epileptic hyperkinetic movements in the context of developmental epileptic encephalopathies is an increasingly recognized phenomenon. Identification of causative mutations provides an important insight into common pathogenic mechanisms that cause both seizures and abnormal motor control. We report bi-allelic loss-of-function CACNA1B variants in six children from three unrelated families whose affected members present with a complex and progressive neurological syndrome. All affected individuals presented with epileptic encephalopathy, severe neurodevelopmental delay (often with regression), and a hyperkinetic movement disorder. Additional neurological features included postnatal microcephaly and hypotonia. Five children died in childhood or adolescence (mean age of death: 9 years), mainly as a result of secondary respiratory complications. CACNA1B encodes the pore-forming subunit of the pre-synaptic neuronal voltage-gated calcium channel Cav2.2/N-type, crucial for SNARE-mediated neurotransmission, particularly in the early postnatal period. Bi-allelic loss-of-function variants in CACNA1B are predicted to cause disruption of Ca2+ influx, leading to impaired synaptic neurotransmission. The resultant effect on neuronal function is likely to be important in the development of involuntary movements and epilepsy. Overall, our findings provide further evidence for the key role of Cav2.2 in normal human neurodevelopment.


Asunto(s)
Canales de Calcio Tipo N/genética , Calcio/metabolismo , Discinesias/genética , Epilepsia/genética , Mutación , Transmisión Sináptica , Adolescente , Niño , Preescolar , Discinesias/patología , Epilepsia/patología , Femenino , Humanos , Lactante , Pérdida de Heterocigocidad , Masculino , Linaje
3.
Connect Tissue Res ; 63(2): 138-150, 2022 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-33588658

RESUMEN

AIM: The healing ability of the anterior cruciate ligament (ACL) injury is very poor; however, it has recently been shown to undergo self-healing with conservative treatments. In this study, we evaluated the influence of the site of injury on the healing process after complete transverse tear of ACL using a rat model. MATERIALS AND METHODS: A total of 58 skeletally mature Wistar rats were randomly assigned to various ACL injury groups: controlled abnormal movement-mid-portion (CAM-MP), controlled abnormal movement-femoral side (CAM-FS), ACL transection-mid-portion (ACLT-MP), or ACL transection-femoral side (ACLT-FS) injury groups. The ACL was completely transected in the mid-portion in the ACLT-MP and CAM-MP groups, and on the femoral side in the ACLT-FS and CAM-FS groups. Both CAM groups underwent extra-articular braking to control for abnormal tibial translation. The animals were allowed full cage activity until sacrifice postoperatively for histological and biomechanical assessment. RESULTS: Significant differences were found in the ratios of residual ligament lengths between the CAM-MP and CAM-FS groups, demonstrating the validity of each model. Spontaneous healing of the injured ACL was observed in the CAM-MP and CAM-FS groups but not in the ACLT-MP and ACLT-FS groups. The mechanical strength of the healing ACL did not differ between the CAM-MP and CAM-FS groups 8 weeks after injury; however, the former had better mechanical strength than the latter 12 weeks after the injury. CONCLUSION: ACL injuries in the mid-portion and on the femoral side may be treated with conservative therapy for spontaneous healing.


Asunto(s)
Lesiones del Ligamento Cruzado Anterior , Discinesias , Animales , Ligamento Cruzado Anterior/cirugía , Lesiones del Ligamento Cruzado Anterior/patología , Discinesias/patología , Articulación de la Rodilla/patología , Ratas , Ratas Wistar , Rotura/patología , Rotura/cirugía
4.
J Med Genet ; 57(2): 132-137, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-31586945

RESUMEN

BACKGROUND: Since 1994, over 50 families affected by the episodic ataxia type 1 disease spectrum have been described with mutations in KCNA1, encoding the voltage-gated K+ channel subunit Kv1.1. All of these mutations are either transmitted in an autosomal-dominant mode or found as de novo events. METHODS: A patient presenting with a severe combination of dyskinesia and neonatal epileptic encephalopathy was sequenced by whole-exome sequencing (WES). A candidate variant was tested using cellular assays and patch-clamp recordings. RESULTS: WES revealed a homozygous variant (p.Val368Leu) in KCNA1, involving a conserved residue in the pore domain, close to the selectivity signature sequence for K+ ions (TVGYG). Functional analysis showed that mutant protein alone failed to produce functional channels in homozygous state, while coexpression with wild-type produced no effects on K+ currents, similar to wild-type protein alone. Treatment with oxcarbazepine, a sodium channel blocker, proved effective in controlling seizures. CONCLUSION: This newly identified variant is the first to be reported to act in a recessive mode of inheritance in KCNA1. These findings serve as a cautionary tale for the diagnosis of channelopathies, in which an unreported phenotypic presentation or mode of inheritance for the variant of interest can hinder the identification of causative variants and adequate treatment choice.


Asunto(s)
Ataxia/genética , Discinesias/genética , Epilepsia/genética , Canal de Potasio Kv.1.1/genética , Miocimia/genética , Ataxia/diagnóstico , Ataxia/tratamiento farmacológico , Ataxia/patología , Canalopatías/diagnóstico , Canalopatías/tratamiento farmacológico , Canalopatías/genética , Canalopatías/patología , Niño , Preescolar , Discinesias/diagnóstico , Discinesias/tratamiento farmacológico , Discinesias/patología , Epilepsia/diagnóstico , Epilepsia/tratamiento farmacológico , Epilepsia/patología , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Homocigoto , Humanos , Lactante , Recién Nacido , Canal de Potasio Kv.1.1/ultraestructura , Masculino , Mutación/genética , Miocimia/diagnóstico , Miocimia/tratamiento farmacológico , Miocimia/patología , Oxcarbazepina/administración & dosificación , Oxcarbazepina/efectos adversos , Linaje , Secuenciación del Exoma
5.
Am J Respir Cell Mol Biol ; 59(3): 375-382, 2018 09.
Artículo en Inglés | MEDLINE | ID: mdl-29481304

RESUMEN

Primary ciliary dyskinesia is an inherited, currently incurable condition. In the respiratory system, primary ciliary dyskinesia causes impaired functioning of the mucociliary escalator, leading to nasal congestion, cough, and recurrent otitis media, and commonly progresses to cause more serious and permanent damage, including hearing deficits, chronic sinusitis, and bronchiectasis. New treatment options for the condition are thus necessary. In characterizing an immortalized human bronchial epithelial cell line (BCi-NS1.1) grown at an air-liquid interface to permit differentiation, we have identified that these cells have dyskinetic motile cilia. The cells had a normal male karyotype, and phenotypic markers of epithelial cell differentiation emerged, as previously shown. Ciliary beat frequency (CBF) as assessed by high-speed videomicroscopy was lower than normal (4.4 Hz). Although changes in CBF induced by known modulators were as expected, the cilia displayed a dyskinetic, circular beat pattern characteristic of central microtubular agenesis with outer doublet transposition. This ultrastructural defect was confirmed by electron microscopy. We propose that the BCi-NS1.1 cell line is a useful model system for examination of modulators of CBF and more specifically could be used to screen for novel drugs with the ability to enhance CBF and perhaps repair a dyskinetic ciliary beat pattern.


Asunto(s)
Diferenciación Celular/fisiología , Cilios/patología , Trastornos de la Motilidad Ciliar/patología , Discinesias/patología , Células Epiteliales/citología , Línea Celular , Células Cultivadas , Humanos
6.
Eur J Nucl Med Mol Imaging ; 45(3): 423-431, 2018 03.
Artículo en Inglés | MEDLINE | ID: mdl-29075830

RESUMEN

PURPOSE: Reduced presynaptic dopaminergic activity plays an important role in the development of levodopa-induced dyskinesia (LID) in Parkinson's disease (PD). In this study, we investigated whether dopaminergic function in the nigrostriatal system is associated with the timing of LID onset. METHODS: From among 412 drug-naive PD patients who underwent a dopamine transporter (DAT) PET scan during their baseline evaluation, we enrolled 65 patients who developed LID during a follow-up period of >2 years. Based on the time from PD onset, LID was classified as early, intermediate or late onset. We then compared DAT availability in the striatal subregions of the patients in the three groups. RESULTS: The demographic characteristics did not differ among the three patient groups except for earlier intervention of levodopa therapy in the early LID onset group (p = 0.001). After adjusting for age at PD onset, gender, timing of levodopa therapy from PD onset, and the severity of PD motor symptoms, DAT activity in the posterior putamen was found to be significantly lower in the early LID onset group than in the late LID onset group (p = 0.017). Multivariate linear regression analysis showed that low DAT activity in the posterior putamen was significantly associated with the early appearance of LID in the early LID onset group (ß = 16.039, p = 0.033). CONCLUSION: This study demonstrated that low DAT activity in the posterior putamen at baseline is a major risk factor for the early onset of LID in patients with PD, suggesting that the degree of presynaptic dopaminergic denervation plays an important role in determining the timing of LID onset.


Asunto(s)
Dopamina/deficiencia , Discinesias/etiología , Discinesias/metabolismo , Levodopa/efectos adversos , Enfermedad de Parkinson/tratamiento farmacológico , Sinapsis/efectos de los fármacos , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/metabolismo , Discinesias/diagnóstico por imagen , Discinesias/patología , Femenino , Humanos , Levodopa/uso terapéutico , Masculino , Persona de Mediana Edad , Tomografía Computarizada por Tomografía de Emisión de Positrones , Pronóstico , Sinapsis/metabolismo , Factores de Tiempo , Tropanos
7.
J Neuroradiol ; 44(1): 24-30, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-27836650

RESUMEN

INTRODUCTION: Hyperglycemia can induce hemichorea-hemiballism, especially in elderly type II diabetics. CT and MRI findings include hyperdensity and T1-shortening in the contralateral lentiform nucleus, respectively. This study explores the associated imaging findings on T2*-based sequences. METHODS: Six patients with clinically documented hyperglycemia-induced hemichorea-hemiballism who had undergone MR imaging with a T2*-based sequence (T2* gradient echo or susceptibility-weighted imaging) were included in this retrospective case series. RESULTS: All six patients demonstrated T1-shortening contralateral to their hemichorea-hemiballism. T2*-based sequences demonstrated unilateral hypointense signal within the striatum in four patients. One patient had mild bilateral striatal hyperintensities, while another did not show significant signal changes. CONCLUSION: It is important for the radiologist to be aware of the signal changes that can be seen on T2*-based sequences in hyperglycemia-induced hemochorea-hemiballism.


Asunto(s)
Encéfalo/diagnóstico por imagen , Corea/diagnóstico por imagen , Discinesias/diagnóstico por imagen , Hiperglucemia/complicaciones , Imagen por Resonancia Magnética/métodos , Adulto , Anciano , Anciano de 80 o más Años , Encéfalo/patología , Corea/etiología , Corea/patología , Discinesias/etiología , Discinesias/patología , Femenino , Humanos , Masculino , Estudios Retrospectivos , Adulto Joven
8.
Malar J ; 15: 461, 2016 09 08.
Artículo en Inglés | MEDLINE | ID: mdl-27609213

RESUMEN

BACKGROUND: Malaria is a mosquito-borne infectious disease with diverse clinical manifestations caused by a parasitic protozoan of the genus Plasmodium. Complex inter-relationships between Mycoplasma species and Plasmodium parasites have been previously noted in vitro. This is the first report of Plasmodium falciparum and Mycoplasma pneumoniae co-infection in a human host presenting with cerebral malaria manifesting orofacial dyskinesias and haemophagocytic lymphohistiocytosis. CASE PRESENTATION: A 55-year-old Sri Lankan man with a recent visit to South Africa presented with an acute febrile illness, cough and worsening dyspnoea with alveolar-interstitial infiltrates on chest radiography. Serological evaluation confirmed a diagnosis of Mycoplasma infection. He subsequently developed encephalopathy with orofacial dyskinesia. A diagnosis of severe P. falciparum infection with significant parasitaemia was established. Peripheral blood cytopaenia occurred due to haemophagocytic lymphohistiocytosis in the bone marrow. Complete clinical and haematological recovery was achieved with intravenous artesunate. CONCLUSIONS: Plasmodium falciparum and Mycoplasma pneumoniae co-infection occurring in vivo manifests clinical features that are plausibly a result of the interaction between the two microorganisms. This is the first report of orofacial dyskinesia in either infection.


Asunto(s)
Coinfección/complicaciones , Discinesias/patología , Linfohistiocitosis Hemofagocítica/patología , Malaria Cerebral/patología , Malaria Falciparum/complicaciones , Infecciones por Mycoplasma/complicaciones , Discinesias/complicaciones , Humanos , Linfohistiocitosis Hemofagocítica/complicaciones , Malaria Cerebral/complicaciones , Masculino , Persona de Mediana Edad , Mycoplasma pneumoniae/aislamiento & purificación , Plasmodium falciparum/aislamiento & purificación , Sudáfrica , Sri Lanka
9.
BMC Neurol ; 16(1): 226, 2016 Nov 17.
Artículo en Inglés | MEDLINE | ID: mdl-27855646

RESUMEN

BACKGROUND: Belly dancer's dyskinesia is an extremely rare condition. It manifests as semicontinuous, slow, writhing, sinuous abdominal wall movements that are bothersome to the patient. Management of this condition is extremely difficult and challenging. METHODS: We describe four patients with belly dancer's dyskinesia who were treated with Botulinum Toxin A (BTX) injections under ultrasound guidance. RESULTS: All patients underwent the same BTX injection procedure using an aseptic technique under ultrasound guidance. The patients responded well to the BTX injections after an unsatisfactory course of medical treatment. The patients reported complete abolishment of abnormal abdominal movements with no side effects. CONCLUSIONS: We report a cohort of patients with belly dancer dyskinesia treated successfully with BTX injections. Ultrasound guidance for injections increases the accuracy and reduces the risk of the complications. BTX injection under ultrasound guidance is a safe and effective treatment modality that should be employed as a first-line in the management of patients with belly dancer's dyskinesia.


Asunto(s)
Músculos Abdominales/fisiopatología , Antidiscinéticos/uso terapéutico , Toxinas Botulínicas Tipo A/uso terapéutico , Discinesias/tratamiento farmacológico , Adulto , Anciano , Antidiscinéticos/administración & dosificación , Toxinas Botulínicas Tipo A/administración & dosificación , Discinesias/diagnóstico por imagen , Discinesias/patología , Femenino , Humanos , Inyecciones Intramusculares , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Resultado del Tratamiento , Ultrasonografía Intervencional
10.
Nature ; 465(7297): 497-501, 2010 May 27.
Artículo en Inglés | MEDLINE | ID: mdl-20463662

RESUMEN

Phosphorylated derivatives of phosphatidylinositol, collectively referred to as phosphoinositides, occur in the cytoplasmic leaflet of cellular membranes and regulate activities such as vesicle transport, cytoskeletal reorganization and signal transduction. Recent studies have indicated an important role for phosphoinositide metabolism in the aetiology of diseases such as cancer, diabetes, myopathy and inflammation. Although the biological functions of the phosphatases that regulate phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P(3)) have been well characterized, little is known about the functions of the phosphatases regulating the closely related molecule phosphatidylinositol-3,4-bisphosphate (PtdIns(3,4)P(2)). Here we show that inositol polyphosphate phosphatase 4A (INPP4A), a PtdIns(3,4)P(2) phosphatase, is a suppressor of glutamate excitotoxicity in the central nervous system. Targeted disruption of the Inpp4a gene in mice leads to neurodegeneration in the striatum, the input nucleus of the basal ganglia that has a central role in motor and cognitive behaviours. Notably, Inpp4a(-/-) mice show severe involuntary movement disorders. In vitro, Inpp4a gene silencing via short hairpin RNA renders cultured primary striatal neurons vulnerable to cell death mediated by N-methyl-d-aspartate-type glutamate receptors (NMDARs). Mechanistically, INPP4A is found at the postsynaptic density and regulates synaptic NMDAR localization and NMDAR-mediated excitatory postsynaptic current. Thus, INPP4A protects neurons from excitotoxic cell death and thereby maintains the functional integrity of the brain. Our study demonstrates that PtdIns(3,4)P(2), PtdIns(3,4,5)P(3) and the phosphatases acting on them can have distinct regulatory roles, and provides insight into the unique aspects and physiological significance of PtdIns(3,4)P(2) metabolism. INPP4A represents, to our knowledge, the first signalling protein with a function in neurons to suppress excitotoxic cell death. The discovery of a direct link between PtdIns(3,4)P(2) metabolism and the regulation of neurodegeneration and involuntary movements may aid the development of new approaches for the treatment of neurodegenerative disorders.


Asunto(s)
Ácido Glutámico/toxicidad , Neuronas/citología , Neuronas/efectos de los fármacos , Monoéster Fosfórico Hidrolasas/metabolismo , Animales , Muerte Celular/efectos de los fármacos , Supervivencia Celular , Células Cultivadas , Regulación hacia Abajo , Discinesias/genética , Discinesias/patología , Discinesias/fisiopatología , Ácido Glutámico/metabolismo , Ácido Glutámico/farmacología , Humanos , Ratones , Ratones Endogámicos C57BL , Neostriado/efectos de los fármacos , Neostriado/metabolismo , Neostriado/patología , Enfermedades Neurodegenerativas/genética , Enfermedades Neurodegenerativas/patología , Enfermedades Neurodegenerativas/fisiopatología , Neuronas/enzimología , Neuronas/patología , Monoéster Fosfórico Hidrolasas/deficiencia , Monoéster Fosfórico Hidrolasas/genética , Receptores de N-Metil-D-Aspartato/metabolismo , Tasa de Supervivencia , Sinapsis/metabolismo , Pérdida de Peso
11.
Ideggyogy Sz ; 68(11-12): 417-21, 2015 Nov 30.
Artículo en Inglés | MEDLINE | ID: mdl-26821516

RESUMEN

Hyperglycaemia induced movement disorders, such as hemiballism are rare disorders. The syndrome is characterised by the triad of hemiballism, contralateral T1-hyperintense striatal lesion and non-ketotic hyperglycaemia. Here we report a patient with untreated diabetes presenting with acute onset of hemiballism. MRI revealed T1 hyperintensity of the head of the caudate nucleus and the anterior putamen. The patient also had acantocytosis. Based on the detailed examination of the neuroradiological results and earlier findings we will discuss the pathomechanism. Based on previous findings microhemorrhages, extensive mineralisation, gemistocytic astrocytosis might play a role in the development of the imaging signs. The connectivity pattern of the striatal lesion showed extensive connections to the frontal cortex. In coexistence with that the most severe impairment was found on the phonemic verbal fluency task measuring frontal executive functions.


Asunto(s)
Trastornos del Conocimiento/etiología , Trastornos del Conocimiento/patología , Cuerpo Estriado/patología , Discinesias/etiología , Función Ejecutiva , Lóbulo Frontal/patología , Hiperglucemia/complicaciones , Trastornos del Habla/etiología , Abetalipoproteinemia/etiología , Abetalipoproteinemia/patología , Adulto , Núcleo Caudado/patología , Complicaciones de la Diabetes/patología , Discinesias/patología , Humanos , Hiperglucemia/patología , Imagen por Resonancia Magnética , Masculino , Memoria a Corto Plazo , Putamen/patología , Trastornos del Habla/patología
12.
Birth Defects Res C Embryo Today ; 102(2): 115-25, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24975753

RESUMEN

Structural birth defect (SBD) is a major cause of morbidity and mortality in the newborn period. Although the etiology of SBD is diverse, a wide spectrum of SBD associated with ciliopathies points to the cilium as having a central role in the pathogenesis of SBDs. Ciliopathies are human diseases arising from disruption of cilia structure and/or function. They are associated with developmental anomalies in one or more organ systems and can involve defects in motile cilia, such as those in the airway epithelia or from defects in nonmotile (primary cilia) that have sensory and cell signaling function. Availability of low cost next generation sequencing has allowed for explosion of new knowledge in genetic etiology of ciliopathies. This has led to the appreciation that many genes are shared in common between otherwise clinically distinct ciliopathies. Further insights into the relevance of the cilium in SBD has come from recovery of pathogenic mutations in cilia-related genes from many large-scale mouse forward genetic screens with differing developmental phenotyping focus. Our mouse mutagenesis screen for congenital heart disease (CHD) using noninvasive fetal echocardiography has yielded a marked enrichment for pathogenic mutations in genes required for motile or primary cilia function. These novel mutant mouse models will be invaluable for modeling human ciliopathies and further interrogating the role of the cilium in the pathogenesis of SBD and CHD. Overall, these findings suggest a central role for the cilium in the pathogenesis of a wide spectrum of developmental anomalies associated with CHD and SBDs.


Asunto(s)
Cilios/patología , Anomalías Congénitas/genética , Modelos Animales de Enfermedad , Animales , Encéfalo/anomalías , Anomalías Congénitas/patología , Discinesias/genética , Discinesias/patología , Cardiopatías Congénitas/genética , Cardiopatías Congénitas/patología , Secuenciación de Nucleótidos de Alto Rendimiento , Ratones , Mutación , Orgánulos/patología , Transducción de Señal
13.
Eur Neurol ; 72(5-6): 340-8, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25322688

RESUMEN

BACKGROUND: Pharmacological treatment of dyskinetic cerebral palsy (CP) is often ineffective. Data about outcome of deep brain stimulation (DBS) in these patients remains scarce. METHODS: Eight patients with dyskinetic CP and DBS of the Globus Pallidus internus were investigated. Using pre- and postoperative videos the severity of dystonia and changes thereof during standardized settings ('on') and after the stimulator had been switched off ('off') were assessed using the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS). Furthermore, subjective impression (SI) of the extent of postoperative change as well as gait (Leonardo Mechanograph® Gangway), speech (Frenchay Dysarthria) and swallowing performances (fiberoptic laryngoscopy) were assessed during 'on' and 'off'. RESULTS: When comparing pre- and postoperative as well as 'on' and 'off', the BFMDRS and most of the gait, speech, and swallowing parameters did not differ significantly. In contrast, patients reported significant improvement of their SI postoperatively (3.1 on a 10-point-scale). CONCLUSION: Data show that our CP-patients did not benefit from GPi-DBS when tested formally for dystonia, gait, speech and swallowing. In stark contrast, these patients reported significant subjective improvement. Taken together, and in light of current unsatisfactory medical treatment options, our data suggest that further assessment of the effects of GPi-DBS in dyskinetic CP is warranted.


Asunto(s)
Parálisis Cerebral/terapia , Estimulación Encefálica Profunda , Deglución , Discinesias/terapia , Marcha , Habla , Adulto , Parálisis Cerebral/patología , Parálisis Cerebral/fisiopatología , Parálisis Cerebral/psicología , Deglución/fisiología , Discinesias/patología , Discinesias/fisiopatología , Discinesias/psicología , Femenino , Tecnología de Fibra Óptica , Marcha/fisiología , Globo Pálido/patología , Globo Pálido/fisiopatología , Humanos , Laringoscopía , Imagen por Resonancia Magnética , Masculino , Índice de Severidad de la Enfermedad , Habla/fisiología , Resultado del Tratamiento , Grabación en Video , Adulto Joven
14.
Metab Brain Dis ; 29(3): 813-24, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-24599759

RESUMEN

In 1949, asterixis was first described in patients with hepatic encephalopathy. It was quickly recognized that this phenomenon also occurs in other generalized encephalopathies and sometimes results from structural brain lesions. This paper is a study of asterixis in the general neurology clinic and on the inpatient neurology consultation service. The neurologists recorded the findings on inpatients and clinic patients for 12 consecutive months. Of the 1,109 inpatients with adequate examination, asterixis was documented in 97. Eighteen of the 97 cases were unilateral (18.6%) and 79 cases were bilateral (81.4%). Of the 614 outpatient visits with well documented examination, 6 (1%) individuals had asterixis. Since a small number of patients were examined more than once, the study yielded 103 individuals with adequate data for analysis. Asterixis resulted from varied causes: medications, renal disorder, hepatic dysfunction, pulmonary insufficiency, stroke and other brain lesions (including malignancy, subdural hematoma, and epidural abscess). Asterixis occurred in various patterns: in some cases it was easier to elicit in the upper extremities, in some it was easier to elicit in the lower limbs, and some it was solely or predominantly unilateral. The findings are discussed in light of the literature on asterixis with regard to its varied causes, patterns and presentations. Lastly, asterixis is examined from a historical perspective and the terminology is elucidated.


Asunto(s)
Encéfalo/patología , Discinesias/diagnóstico , Discinesias/patología , Humanos , Índice de Severidad de la Enfermedad , Evaluación de Síntomas
16.
Arch Endocrinol Metab ; 68: e220413, 2024 03 25.
Artículo en Inglés | MEDLINE | ID: mdl-38530964

RESUMEN

Nonketotic hyperglycemia may occur as a cause of chorea in patients with chronic decompensated diabetes. Because it is rare and consequently poorly studied, diagnosis and treatment can be delayed. Therefore, our objective was to summarize clinical and radiological features, as well as treatments performed, from previously reported cases to facilitate adequate management in clinical practice. We searched MEDLINE/PubMed, EMBASE, Cochrane, CINAHL, Web of Science, Scopus, and LILACS databases for studies published before April 23, 2021. We included case reports and case series of adults (aged ≥ 18 years) that described hyperglycemic chorea with measurement ofglycated hemoglobin (HbA1c) and cranial magnetic resonance imaging (MRI). Studies were excluded if participants were pregnant women, aged < 18 years, and had no description of chorea and/or physical examination. We found 121 studies that met the inclusion criteria, for a total of 214 cases. The majority of the included studies were published in Asia (67.3%). Most patients were women(65.3%) aged > 65 years (67.3%). Almost all patients had decompensated diabetes upon arrival at the emergency department (97.2%). The most common MRI finding was abnormalities of the basal ganglia (89.2%). There was no difference in patient recovery between treatment with insulin alone and in combination with other medications. Although rare, hyperglycemic chorea is a reversible cause of this syndrome; therefore, hyperglycemia should always be considered in these cases.


Asunto(s)
Corea , Diabetes Mellitus , Discinesias , Hiperglucemia , Embarazo , Adulto , Humanos , Femenino , Masculino , Corea/diagnóstico , Corea/etiología , Corea/patología , Discinesias/diagnóstico , Discinesias/etiología , Discinesias/patología , Imagen por Resonancia Magnética/efectos adversos , Hiperglucemia/tratamiento farmacológico
17.
J Neurosci ; 31(44): 15727-31, 2011 Nov 02.
Artículo en Inglés | MEDLINE | ID: mdl-22049415

RESUMEN

Fast-spiking interneurons (FSIs) can exert powerful control over striatal output, and deficits in this cell population have been observed in human patients with Tourette syndrome and rodent models of dystonia. However, a direct experimental test of striatal FSI involvement in motor control has never been performed. We applied a novel pharmacological approach to examine the behavioral consequences of selective FSI suppression in mouse striatum. IEM-1460, an inhibitor of GluA2-lacking AMPARs, selectively blocked synaptic excitation of FSIs but not striatal projection neurons. Infusion of IEM-1460 into the sensorimotor striatum reduced the firing rate of FSIs but not other cell populations, and elicited robust dystonia-like impairments. These results provide direct evidence that hypofunction of striatal FSIs can produce movement abnormalities, and suggest that they may represent a novel therapeutic target for the treatment of hyperkinetic movement disorders.


Asunto(s)
Potenciales de Acción/fisiología , Cuerpo Estriado/patología , Discinesias/etiología , Discinesias/patología , Interneuronas/fisiología , Adamantano/efectos adversos , Adamantano/análogos & derivados , Análisis de Varianza , Animales , Área Bajo la Curva , Antagonistas Colinérgicos/efectos adversos , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Antagonistas de Aminoácidos Excitadores/efectos adversos , Potenciales Postsinápticos Excitadores/efectos de los fármacos , Potenciales Postsinápticos Excitadores/genética , Femenino , Lateralidad Funcional/efectos de los fármacos , Lateralidad Funcional/fisiología , Proteínas Fluorescentes Verdes/genética , Interneuronas/clasificación , Interneuronas/efectos de los fármacos , Proteínas con Homeodominio LIM/genética , Masculino , Mecamilamina/efectos adversos , Ratones , Ratones Transgénicos , N-Metilaspartato/farmacología , Proteínas del Tejido Nervioso/genética , Escopolamina/efectos adversos , Factores de Transcripción/genética
18.
Cell Death Dis ; 13(6): 559, 2022 06 21.
Artículo en Inglés | MEDLINE | ID: mdl-35729109

RESUMEN

Primary cilia dyskinesia (PCD) is a rare genetic disease caused by ciliary structural or functional defects. It causes severe outcomes in patients, including recurrent upper and lower airway infections, progressive lung failure, and randomization of heterotaxy. To date, although 50 genes have been shown to be responsible for PCD, the etiology remains elusive. Meanwhile, owing to the lack of a model mimicking the pathogenesis that can be used as a drug screening platform, thereby slowing the development of related therapies. In the current study, we identified compound mutation of DNAH9 in a patient with PCD with the following clinical features: recurrent respiratory tract infections, low lung function, and ultrastructural defects of the outer dynein arms (ODAs). Bioinformatic analysis, structure simulation assay, and western blot analysis showed that the mutations affected the structure and expression of DNAH9 protein. Dnah9 knock-down (KD) mice recapitulated the patient phenotypes, including low lung function, mucin accumulation, and increased immune cell infiltration. Immunostaining, western blot, and co-immunoprecipitation analyses were performed to clarify that DNAH9 interacted with CCDC114/GAS8 and diminished their protein levels. Furthermore, we constructed an airway organoid of Dnah9 KD mice and discovered that it could mimic the key features of the PCD phenotypes. We then used organoid as a drug screening model to identify mitochondrial-targeting drugs that can partially elevate cilia beating in Dnah9 KD organoid. Collectively, our results demonstrated that Dnah9 KD mice and an organoid model can recapture the clinical features of patients with PCD and provide an excellent drug screening platform for human ciliopathies.


Asunto(s)
Dineínas Axonemales , Discinesias , Síndrome de Kartagener , Animales , Dineínas Axonemales/genética , Dineínas Axonemales/metabolismo , Cilios/metabolismo , Evaluación Preclínica de Medicamentos , Dineínas/metabolismo , Discinesias/metabolismo , Discinesias/patología , Humanos , Síndrome de Kartagener/genética , Síndrome de Kartagener/metabolismo , Síndrome de Kartagener/patología , Ratones , Mutación/genética , Organoides/metabolismo
19.
Neurobiol Dis ; 41(2): 291-8, 2011 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-20955797

RESUMEN

Central pathophysiological pathways of basal ganglia dysfunction imply a disturbed interaction of dopaminergic and cholinergic circuits. In Parkinson's disease (PD) imbalanced cholinergic hyperactivity prevails in the striatum. Interruption of acetylcholine (ACh) release in the striatum by locally injected botulinum neurotoxin A (BoNT-A) has been studied in the rat 6-hydroxydopamine (6-OHDA) model of PD (hemi-PD). The hemi-PD was induced by injection of 6-OHDA into the right medial forebrain bundle. Motor dysfunction provoked by apomorphine-induced contralateral rotation was completely reversed for more than 3 months by ipsilateral intrastriatal application of 1-2 ng BoNT-A. Interestingly, BoNT-A injected alone into the right striatum of naïve rats caused a slight transient ipsilateral apomorphine-induced rotation, which lasted only for about one month. Immunohistochemically, large axonal swellings appeared within the striatum injected with BoNT-A, which we tentatively named BoNT-A-induced varicosities. They contained either choline acetyltransferase or tyrosine hydroxylase. These findings suggest a selective inhibition of evoked release of ACh by locally applied BoNT-A. Intrastriatal application of BoNT-A may antagonize localized relative functional disinhibited hypercholinergic activity in neurodegenerative diseases such as PD avoiding side effects of systemic anti-cholinergic treatment.


Asunto(s)
Axones/patología , Toxinas Botulínicas Tipo A/uso terapéutico , Cuerpo Estriado/efectos de los fármacos , Regeneración Nerviosa/efectos de los fármacos , Oxidopamina/toxicidad , Trastornos Parkinsonianos/tratamiento farmacológico , Trastornos Parkinsonianos/patología , Rotación/efectos adversos , Animales , Axones/fisiología , Cuerpo Estriado/patología , Cuerpo Estriado/fisiopatología , Modelos Animales de Enfermedad , Discinesias/tratamiento farmacológico , Discinesias/patología , Discinesias/fisiopatología , Conos de Crecimiento/efectos de los fármacos , Conos de Crecimiento/patología , Conos de Crecimiento/ultraestructura , Masculino , Regeneración Nerviosa/fisiología , Neurotoxinas/uso terapéutico , Trastornos Parkinsonianos/etiología , Ratas , Ratas Wistar
20.
Ann Neurol ; 68(1): 70-80, 2010 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-20582986

RESUMEN

OBJECTIVE: Exposure to a number of drugs, chemicals, or environmental factors can cause parkinsonism. Epidemiologic evidence supports a causal link between the consumption of flour made from the washed seeds of the plant Cycas micronesica by the Chamorro population of Guam and the development of amyotrophic lateral sclerosis/parkinsonism dementia complex. METHODS: We now report that consumption of washed cycad flour pellets by Sprague-Dawley male rats induces progressive parkinsonism. RESULTS: Cycad-fed rats displayed motor abnormalities after 2 to 3 months of feeding such as spontaneous unilateral rotation, shuffling gait, and stereotypy. Histological and biochemical examination of brains from cycad-fed rats revealed an initial decrease in the levels of dopamine and its metabolites in the striatum (STR), followed by neurodegeneration of dopaminergic (DAergic) cell bodies in the substantia nigra (SN) pars compacta (SNc). alpha-Synuclein (alpha-syn; proteinase K-resistant) and ubiquitin aggregates were found in the DAergic neurons of the SNc and neurites in the STR. In addition, we identified alpha-syn aggregates in neurons of the locus coeruleus and cingulate cortex. No loss of motor neurons in the spinal cord was found after chronic consumption of cycad flour. In an organotypic slice culture of the rat SN and the striatum, an organic extract of cycad causes a selective loss of dopamine neurons and alpha-syn aggregates in the SN. INTERPRETATION: Cycad-fed rats exhibit progressive behavioral, biochemical, and histological hallmarks of parkinsonism, coupled with a lack of fatality.


Asunto(s)
Cycas/toxicidad , Neurotoxinas/toxicidad , Trastornos Parkinsonianos/etiología , Animales , Encéfalo/metabolismo , Encéfalo/patología , Dieta , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Discinesias/etiología , Discinesias/metabolismo , Discinesias/patología , Harina/toxicidad , Técnicas In Vitro , Masculino , Degeneración Nerviosa/etiología , Degeneración Nerviosa/metabolismo , Degeneración Nerviosa/patología , Neuronas/metabolismo , Neuronas/patología , Neurotoxinas/administración & dosificación , Trastornos Parkinsonianos/metabolismo , Trastornos Parkinsonianos/patología , Extractos Vegetales/toxicidad , Ratas , Ratas Sprague-Dawley , Médula Espinal/metabolismo , Médula Espinal/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA